Home › Trials › NCT06024928
Clinical trial No longer in our active list Interventional Ages 18 and up

Automated Insulin Delivery for Managing Type 2 Diabetes

Official title: Short Use of Automated Insulin Delivery (AID) for Basal Insulin Titration in Type 2 Diabetes: A Pilot Study

Run by University of Virginia · NCT06024928 · Data updated 2026-05-14

This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.

This study is testing if an automated insulin delivery system can help people with Type 2 Diabetes manage their blood sugar better than standard methods.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment20 (estimated)
SponsorUniversity of Virginia
Academic / other
Locations1 site (Charlottesville, Virginia)
Trial IDNCT06024928 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18 and older with a clinical diagnosis of Type 2 Diabetes for at least one year and an HbA1c of 7.5% or higher.

Probably not a fit

Patients who are not currently using long-acting insulin or those who are not willing to discontinue their personal CGM during the study may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the safety and feasibility of using an Automated Insulin Device (AID) for basal insulin titration in individuals with Type 2 Diabetes. Participants will be randomly assigned to either a control group or an experimental group, where the latter will use a Tandem t:slim Insulin Pump with Control-IQ Technology for ten days. The study will involve a 10-day run-in phase with a blinded Continuous Glucose Monitor (CGM) followed by a maintenance phase. Researchers will compare glycemic control between the two groups to assess the effectiveness of the AID system.

Why it matters

Potential benefit: If successful, this approach could lead to improved insulin management and better glycemic control for patients with Type 2 Diabetes.

How similar studies have gone: Previous studies have shown promise in using automated insulin delivery systems for diabetes management, indicating potential success for this approach.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

1. Age ≥18.0 years old at time of consent.
2. Clinical diagnosis, based on investigator assessment, of type 2 diabetes for at least one year.
3. HbA1c ≥ 7.5%.
4. Currently using an approved long-acting insulin for at least six months (e.g., insulin glargine, insulin degludec)
5. Willingness to discontinue a personal CGM during the duration of the study.
6. Access to the internet and willingness to upload data during the study as needed.
7. If female and sexually active, must agree to use a form of contraception to prevent pregnancy while a participant in the study. A negative serum or urine pregnancy test will be required for all females of childbearing potential. Participants who become pregnant will be discontinued from the study. Also, participants who during the study develop and express the intention to become pregnant within the timespan of the study will be discontinued.
8. Willingness not to start any new non-insulin glucose-lowering agent during the trial (including metformin/biguanides, Glucagon-like peptide (GLP)-1 receptor agonists, pramlintide, Dipeptidyl peptidase (DPP)-4 inhibitors, sulfonylureas and nutraceuticals).

Exclusion Criteria:

1. Treatment with meglitinides/sulfonylureas.
2. Currently using an approved intermediate (e.g., insulin Neutral Protamine Hagedorn (NPH)) or rapid insulin for at least six months (e.g., insulin aspart, insulin lispro, insulin regular).
3. Currently being treated for a seizure disorder.
4. A known medical condition that in the judgment of the investigator might interfere with the completion of the protocol, such as but not limited to, the following examples: a) Inpatient psychiatric treatment in the past 6 months, b) Presence of a known adrenal disorder, c) Uncontrolled thyroid disease.
5. Currently pregnant or intent to become pregnant during the trial.
6. Currently breastfeeding.
7. Anticipated surgical, interventional procedures or prolonged periods of fasting during this study.
8. History of hypoglycemia unawareness.

Where it's running

  • University of Virginia Center for Diabetes Technology
    Charlottesville, Virginia, United States     Recruiting

Study contacts

  • Principal investigator: Anas El Fathi, PhD — University of Virginia Center for Diabetes Technology
  • Study coordinator: Lianna Smith
  • Email: lhs7px@uvahealth.org
  • Phone: 434-243-6681

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Type 2 Diabetes 581University of Virginia 989
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.